AR059517A1 - N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo - Google Patents

N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo

Info

Publication number
AR059517A1
AR059517A1 ARP070100655A ARP070100655A AR059517A1 AR 059517 A1 AR059517 A1 AR 059517A1 AR P070100655 A ARP070100655 A AR P070100655A AR P070100655 A ARP070100655 A AR P070100655A AR 059517 A1 AR059517 A1 AR 059517A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
group
methylmorpholine
halogen
Prior art date
Application number
ARP070100655A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059517A1 publication Critical patent/AR059517A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1:Un proceso para preparar un alcohol sustituido con sulfonamida-trifluoralquilo que presenta una estructura donde R1 y R2 se seleccionan con independencia entre si del grupo que consiste en H, alquilo C1-6, alquilo sustituido C1-6, CF3, alquenilo C2-6, alquenilo sustituido C2-6, alquinilo C2-6 y alquinilo sustituido C2-6; R3 se selecciona del grupo que consiste en H, alquilo C1-6 y alquilo sustituido C1-6; R4 se selecciona del grupo que consiste en alquilo(CF3)n, (CF3)n(alquilo sustituido), (CF3)nalquilfenilo, (CF3)nalquil(fenilo sustituido) y (F)ncicloalquilo; n es 1 a 3; R5 se selecciona del grupo que consiste en H, halogeno y CF3; W, Y y Z se seleccionan con independencia entre si del grupo que consiste en C, CR6 y N, en donde por lo menos uno de W, Y o Z es C; X se selecciona del grupo que consiste en O, S, SO2 y NR7, R6 se selecciona del grupo que consiste en H, halogeno, alquilo C1-6alquilo y alquilo sustituido C1-6; R7 se selecciona del grupo que consiste en H, alquilo C1-6 y cicloalquilo C3-8, R8, R9, R10, R11 y R12 se seleccionan con independencia entre si del grupo que consiste en H, halogeno, alquilo C1-6, alquilo sustituido C1-6, alcoxi C1-6, alcoxi sustituido C1-6 y NO2; o y R8 y ; R9 y R10; R11 y R12, o R10 y R11 se fusionan para formar: (i) un anillo saturado con base de carbono que contiene 3 a 8 átomos de carbono; (ji) un anillo insaturado con base de carbono que contiene 3 a 8 átomos de carbono; o (iii) un anillo heterocíclico que contiene 1 a 3 heteroátomos seleccionados del grupo que consiste en O, N y S en la estructura de dicho anillo; donde los anillos (i) a (iii) están sustituidos optativamente con 1 a 3 sustituyentes que comprenden alquilo C1-6 o alquilo sustituido C1-6, o un profármaco, hidrato o sal farmacéuticamente aceptable de los mismos; dicho proceso comprende hacer reaccionar un amino alcohol sustituido con trifluoralquilo, un cloruro de sulfonilo y un sistema de base/solvente seleccionado del grupo que consiste en (a) 4-metilmorfolina/ acetato de isopropilo, (b) tetrahidrofurano/base de Hünig, (c) 4-metilmorfolina/acetonitrilo, (d) 4-metil morfolina/propionitrilo y (e) 4-metilmorfolina/tolueno.
ARP070100655A 2006-02-17 2007-02-15 N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo AR059517A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77430006P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
AR059517A1 true AR059517A1 (es) 2008-04-09

Family

ID=38124142

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100655A AR059517A1 (es) 2006-02-17 2007-02-15 N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo

Country Status (18)

Country Link
US (1) US7838550B2 (es)
EP (1) EP1984347A1 (es)
JP (1) JP2009527476A (es)
KR (1) KR20080094685A (es)
CN (1) CN101384579A (es)
AR (1) AR059517A1 (es)
AU (1) AU2007217966A1 (es)
BR (1) BRPI0707742A2 (es)
CA (1) CA2637615A1 (es)
CR (1) CR10158A (es)
EC (1) ECSP088684A (es)
GT (1) GT200800154A (es)
IL (1) IL192929A0 (es)
NO (1) NO20083488L (es)
PE (1) PE20080109A1 (es)
RU (1) RU2008131051A (es)
TW (1) TW200732295A (es)
WO (1) WO2007098030A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002357333B2 (en) * 2001-12-20 2008-02-28 Bristol-Myers Squibb Company Alpha-(N-sulphonamido)acetamide derivatives as Beta-amyloid inhibitors
CN101274926A (zh) * 2003-03-31 2008-10-01 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
PE20090824A1 (es) * 2007-07-16 2009-07-24 Wyeth Corp Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas
PE20090445A1 (es) * 2007-07-16 2009-05-18 Wyeth Corp Inhibidores de produccion de beta amiloide
US20090023930A1 (en) * 2007-07-16 2009-01-22 Wyeth Processes and intermediates for the preparation of heterocyclic sulfonamide compounds
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP2278878A4 (en) * 2008-05-08 2014-08-27 Bristol Myers Squibb Co 2-ARYL-GYCINAMID DERIVATIVES
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) * 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795890A (en) 1995-09-27 1998-08-18 Ono Pharmaceutical Co., Ltd. Sulfonamide derivatives
JPH09241262A (ja) 1996-03-08 1997-09-16 Kao Corp ３−オキサ−２，７−ジアザビシクロ〔３．３．０〕オクタン誘導体
US5962231A (en) * 1997-09-30 1999-10-05 Incyte Pharmaceuticals, Inc. Human glutathione-S-transferase
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US6803365B2 (en) * 1999-12-24 2004-10-12 Bayer Aktlengesellschaft Imidazo[1,3,5]triazinones and the use thereof
ES2231311T3 (es) * 1999-12-24 2005-05-16 Bayer Healthcare Ag Triazolotriazinonas y su uso.
US6657070B2 (en) * 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
MXPA03005255A (es) * 2000-12-13 2004-10-14 Wyeth Corp Inhibidores de produccion de beta-amiloide de sulfonamida heterociclica.
NZ533432A (en) * 2001-12-11 2006-01-27 Wyeth Corp Process for the synthesis of chirally pure beta-amino-alcohols
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
US7288547B2 (en) * 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1549306A4 (en) * 2002-06-11 2007-06-06 Wyeth Corp PHENYLSULFONAMIDE SUBSTITUTED INHIBITORS OF BETA-AMYLOID PRODUCTION
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
CN101274926A (zh) * 2003-03-31 2008-10-01 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
BRPI0506765A (pt) * 2004-01-16 2007-05-22 Wyeth Corp composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
JP2009528281A (ja) * 2006-02-17 2009-08-06 ワイス スルホンアミド置換アルコールおよびその中間体の調製方法

Also Published As

Publication number Publication date
WO2007098030A8 (en) 2007-10-25
ECSP088684A (es) 2008-09-29
TW200732295A (en) 2007-09-01
BRPI0707742A2 (pt) 2011-05-10
JP2009527476A (ja) 2009-07-30
RU2008131051A (ru) 2010-03-27
US20070197800A1 (en) 2007-08-23
CN101384579A (zh) 2009-03-11
IL192929A0 (en) 2009-02-11
NO20083488L (no) 2008-09-05
CR10158A (es) 2008-10-29
PE20080109A1 (es) 2008-04-01
AU2007217966A1 (en) 2007-08-30
CA2637615A1 (en) 2007-08-30
EP1984347A1 (en) 2008-10-29
GT200800154A (es) 2008-10-21
US7838550B2 (en) 2010-11-23
WO2007098030A1 (en) 2007-08-30
KR20080094685A (ko) 2008-10-23

Similar Documents

Publication Publication Date Title
AR059517A1 (es) N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR061372A1 (es) Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion
AR053773A1 (es) Procedimientos para preparar compuestos de indazol
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
PE20091066A1 (es) 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios
AR068075A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
ES2954474T3 (es) Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
ECSP088479A (es) Derivados de oxadiazol
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
RU2012116208A (ru) Способ получения n-ацилбифенилаланина
DOP2011000083A (es) Compuestos de amida utiles en terapia
ES2655265T3 (es) Procedimiento de preparación de bifenilanilidas sustituidas
AR049121A1 (es) Compuestos quimicos que contienen anillos de oxazolidinona e isoxazolina sustituida
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR057525A1 (es) Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
ES2530815T3 (es) Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas
AR049668A1 (es) Proceso quimico para preparar esteres de 4,4 - difluorometil - 3 - oxo - butanoico por reaccion entre una amida y un ester.

Legal Events

Date Code Title Description
FB Suspension of granting procedure